First Quarter Revenues of $280.1 Million, up 28.5% on a Reported Basis and up 28.1% on a Constant Currency Basis; Adjusted EBITDA up 20.7% on a Reported Basis and up 20.7% on a Constant Currency Basis; Company Updates Guidance, Announces Quarterly Dividend and Provides Supplemental Information
WESTLAKE, Texas , Nov.
- 9.4% growth in consolidated service revenue to $491.7 million - Gross margin improvements in all three business segments year-over-year - GAAP operating margin of 10.9%; adjusted operating margin of 10.7% (up 140 basis points)
- GAAP diluted earnings per share of $0.67 grew 48.9%; adjusted diluted earnings per share of $0.65 grew 44.4% - Net new business wins of $432 million; net book-to-bill ratio of 0.88; backlog at $4.9 billion BOSTON , Oct.
Sevion Therapeutics, Inc. ("Sevion" or the "Company") (OTCQB:SVON), a
biopharmaceutical company which discovers, develops and acquires
next-generation biologics for the treatment of cancer and immunological
diseases, today reported financial results for the fiscal quarter ended
September 30, 2014 (“First Quarter 2015”).
"During the first fiscal quarter of 2015, we made a strategic decision
to focus our efforts and resources on our proprietary antibody discovery
technology platforms, including two promising antibodies that are
advancing toward IND status,” said Ronald Martell, Chief Executive
Officer of Sevion.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.